| Literature DB >> 30510492 |
Margarita Kirienko1, Martina Sollini1,2, Giorgia Silvestri3, Serena Mognetti3, Emanuele Voulaz4, Lidija Antunovic2, Alexia Rossi1,5, Luca Antiga3, Arturo Chiti1,2.
Abstract
Aim: To develop an algorithm, based on convolutional neural network (CNN), for the classification of lung cancer lesions as T1-T2 or T3-T4 on staging fluorodeoxyglucose positron emission tomography (FDG-PET)/CT images.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30510492 PMCID: PMC6232785 DOI: 10.1155/2018/1382309
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.161
Figure 1Study workflow and networks' architecture. The network (consisting of two neural networks, the feature extractor, and the classifier) was trained using a cross-validation strategy. The entire dataset was divided into 5 randomly chosen parts. At each training run, 4/5 of the dataset were used as a training set and the remaining 1/5 was used as the validation set. Subsequently, the final model network was adjusted and tested for performance using the dataset divided into three sets: training, validation, and test. In the feature extractor CNN, the input images, both PET and CT, were submitted to a series of convolutions producing a stack of feature maps containing low-level features, rectified linear units (ReLU), and max pooling layers that downsample the feature maps (MaxPool), to produce higher-level features. In the classifier network, these higher-level features are used to perform the final classification T1-T2 (output label 0) vs T3-T4 (output label 1).
Summary of the parameters of the feature extractor and the classifier networks.
| Feature extractor | Classifier | |
|---|---|---|
| Loss function | Cross entropy | Weight cross entropy |
| Learning method | Adam | Adam |
| Learning rate | 1 | 1 |
| Weight decay | 1 | 1 |
| Epochs | 600 | 600 |
| Patients/batch | 2 | 2 |
| Slides/patient | 20 | n.a. |
n.a.: not applicable.
Patients' characteristics.
| Characteristics | Patients, |
|---|---|
| Age (year): mean: 69 ± 9, median: 69 (range: 36–112) | |
|
| |
|
| |
| Male | 316 (67) |
| Female | 156 (33) |
|
| |
|
| |
| Adenocarcinoma | 317 (67) |
| Squamous cell carcinoma | 155 (33) |
|
| |
|
| |
| T1 | 159 (34) |
| T2 | 194 (41) |
| T3 | 79 (17) |
| T4 | 40 (8) |
| N0 | 259 (55) |
| N1 | 94 (20) |
| N2 | 103 (22) |
| N3 | 16 (3) |
| M0 | 472 (100) |
|
| |
|
| |
| I | 193 (41) |
|
| 115 (24) |
|
| 78 (17) |
|
| |
| II | 116 (25) |
|
| 66 (14) |
|
| 50 (11) |
|
| |
| III | 163 (34) |
|
| 129 (27) |
|
| 34 (7) |
The stage was clinically assessed in 97 patients (20%), while in the remaining 375 cases (80%), it was pathologically assessed.
Results of the cross-validation analysis.
| Training ( | Validation ( | |||||
|---|---|---|---|---|---|---|
| Accuracy (%) | Recall (%) | Specificity (%) | Accuracy (%) | Recall (%) | Specificity (%) | |
| CV 1 | 82.6 | 91.2 | 56.8 | 76.6 | 84.3 | 54.2 |
| CV 2 | 87.3 | 95.8 | 62.1 | 76.6 | 91.4 | 33.3 |
| CV 3 | 78.4 | 91.2 | 40.6 | 81.9 | 90.0 | 58.3 |
| CV 4 | 85.0 | 88.3 | 75.0 | 73.4 | 81.7 | 47.8 |
| CV 5 | 79.7 | 94.0 | 36.8 | 78.7 | 94.3 | 33.3 |
| Mean | 82.6 | 92.1 | 53.4 | 77.4 | 88.3 | 45.4 |
CV: cross validation.
Results of the final model.
| Accuracy (%) | Recall (%) | Specificity (%) | Area under the curve | |
|---|---|---|---|---|
| Training ( | 86.8 | 85.9 | 89.5 | 0.83 |
| Validation ( | 69.3 | 76.8 | 47.4 | 0.73 |
| Test ( | 69.1 | 70.0 | 66.7 | 0.68 |
Figure 2Clinical examples of the network classification. Axial CT images (a, b) of a patient affected by lung adenocarcinoma pT1bN0 ((a) zoom on the lesion); the developed neural network classified the new input image ((b) green square on one of the slices in which the lesion is visible) as belonging to the class T1-T2 with 99% probability. Axial CT images (c, d) of a patient affected by lung adenocarcinoma pT4N1 ((c) zoom on the lesion); the developed neural network classified the new input image ((d) green square on one of the slices in which the lesion is visible) as belonging to the class T3-T4 with 92% probability.